Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human phase I trial of ZI-MA4-1 an open-label, dose-escalation basket study evaluating the safety, tolerability and preliminary efficacy of ZI-MA4-1 across multiple solid tumours

Next Previous
Trial Profile

A first-in-human phase I trial of ZI-MA4-1 an open-label, dose-escalation basket study evaluating the safety, tolerability and preliminary efficacy of ZI-MA4-1 across multiple solid tumours

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZI-MA4-1 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Zelluna ASA; Zelluna Immunotherapy

Most Recent Events

  • 30 Oct 2025 New trial record
  • 09 Oct 2025 According to a Zelluna Immunotherapy media release, the company remains on track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026
  • 20 Aug 2025 Accoridng to a Zelluna Immunotherapy media release, following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top